Fig. 7

The distribution of free DIR, PHBV-PTX-NPs, PDA-PHBV-PTX-NPs and RGD-PDA-PHBV-PTX-NPs toward HepG2 tumor-bearing mice. a In vivo NIRF imaging in the tumor areas of the xenograft mouse model treated with free DIR, PHBV-PTX-NPs, PDA-PHBV-PTX-NPs and RGD-PDA-PHBV-PTX-NPs at 1, 4, 8, 12, 24 and 48 h tail vein injection. b In vivo fluorescence images of major organs of the xenograft mouse model at the end of the experiment. c Average NIRF intensity in the tumor areas. d Quantitative examination of nanoparticles in the tumor and main organs at 48 h tail vein injection, and each point represents the mean ± SD (n = 3). Student's t-test, *p < 0.05; **p < 0.01, ***p < 0.001. PHBV, ploy (3-hydroxybutyrate-co-3-hydroxyvalerate); PTX, paclitaxel; PDA, polydopamine; NPs, nanoparticles